Celldex Therapeutics moved to discontinue its mast cell-targeting monoclonal antibody barzolvolimab in prurigo nodularis after a phase II study missed its primary and key secondary endpoints. The company cited that the topline results did not support continued development in the chronic itch indication. The failure shifts attention back to Celldex’s broader pipeline, including ongoing work in other dermatology and allergic disease areas. Investors will also be watching whether barzolvolimab’s remaining clinical programs can preserve the development narrative after the phase II setback. Celldex said it will continue testing barzolvolimab in other indications, with additional data timing dependent on those ongoing trials.